title: A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
abstract: Esophageal adenocarcinoma (EAC) has become the dominant type of esophageal cancer in United States. The 5-year survival rate of EAC is below 20% and most patients present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Improvement of EAC patient outcome requires well-characterized animal models in which to evaluate novel therapeutics. In this study we aimed to establish a peritoneal dissemination xenograft mouse model of EAC that would support survival outcome analyses. To find the best candidate cell line from 7 human EAC cell lines of different origin named ESO26, OE33, ESO51, SK-GT-2, OE19, OACM5.1C and Flo-1 were injected intraperitoneally/subcutaneously into SCID mice. The peritoneal/xenograft tumor formation and mouse survival were compared among different groups. All cell lines injected subcutaneously formed tumors within 3 months at variable rates. All cell lines except OACM5.1C formed intraperitoneal tumors within 3 months at variable rates. Median animal survival with peritoneal dissemination was 108 days for ESO26 cells (5X106), 65 days for OE33 cells (5X106), 88 days for ESO51 cells (5X106), 76 days for SK-GT-2 cells (5X106), 55 days for OE19 cells (5X106), 45 days for OE19 cells (10X106) and 82 days for Flo-1 cells (5X106). Interestingly, only in the OE19 model all mice (7/7 for 5X106 and 5/5 for10X106) developed bloody ascites with liver metastasis after intraperitoneal injection. The median survival time of these animals was the shortest (45 days for 10X106 cells). In addition, median survival was significantly increased after paclitaxel treatment compared with the control group (57 days versus 45 days, p = 0.0034) along with a significant decrease of the relative subcutaneous tumor volume (p = 0.00011). Thus peritoneal dissemination mouse xenograft model for survival outcome assessment after intraperitoneal injection of OE19 cells will be very useful for the evaluation of cancer therapeutics.
authors.affiliation: Department of Surgery, Indiana University School of Medicine, South Bend, IN, United States of America.|Harper Cancer Research Institute, South Bend, IN, United States of America.
authors.forename: Md Sazzad
authors.identifier: 0000-0001-6309-9616
authors.initials: MS
authors.lastname: Hassan
authors.affiliation: Department of Surgery, Indiana University School of Medicine, South Bend, IN, United States of America.|Harper Cancer Research Institute, South Bend, IN, United States of America.
authors.forename: Niranjan
authors.initials: N
authors.lastname: Awasthi
authors.affiliation: Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN, United States of America.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Surgery, Indiana University School of Medicine, South Bend, IN, United States of America.|Harper Cancer Research Institute, South Bend, IN, United States of America.|Department of Pediatrics, Indiana University School of Medicine, South Bend, IN, United States of America.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Schwarz
authors.affiliation: Department of Surgery, Indiana University School of Medicine, South Bend, IN, United States of America.|Harper Cancer Research Institute, South Bend, IN, United States of America.|Goshen Center for Cancer Care, Goshen, Goshen, IN, United States of America.
authors.forename: Roderich E
authors.initials: RE
authors.lastname: Schwarz
authors.affiliation: Department of Surgery, Indiana University School of Medicine, South Bend, IN, United States of America.|Harper Cancer Research Institute, South Bend, IN, United States of America.|Goshen Center for Cancer Care, Goshen, Goshen, IN, United States of America.|University of Basel, Basel, Switzerland.
authors.forename: Urs
authors.initials: U
authors.lastname: von Holzen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D064593:Heterografts; D051379:Mice; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel